Author Archives: admin


Global Cell Therapy Technologies Market Industry Analysis and Forecast (2018-2026) – Markets Gazette

Global Cell Therapy Technologies Market was valued US$ 12 billion in 2018 and is expected to reach US$ 35 billion by 2026, at CAGR of 12.14 %during forecast period.

The objective of the report is to present comprehensive assessment projections with a suitable set of assumptions and methodology. The report helps in understanding Global Cell Therapy Technologies Market dynamics, structure by identifying and analyzing the market segments and projecting the global market size. Further, the report also focuses on the competitive analysis of key players by product, price, financial position, growth strategies, and regional presence. To understand the market dynamics and by region, the report has covered the PEST analysis by region and key economies across the globe, which are supposed to have an impact on market in forecast period. PORTERs analysis, and SVOR analysis of the market as well as detailed SWOT analysis of key players has been done to analyze their strategies. The report will to address all questions of shareholders to prioritize the efforts and investment in the near future to the emerging segment in the Global Cell Therapy Technologies Market.

Request For Free Sample Report : https://www.maximizemarketresearch.com/market-report/global-cell-therapy-technologies-market/31531/#requestforsample

Global Cell Therapy Technologies Market: OverviewCell therapy is a transplantation of live human cells to replace or repair damaged tissue and/or cells. With the help of new technologies, limitless imagination, and innovative products, many different types of cells may be used as part of a therapy or treatment for different types of diseases and conditions. Celltherapy technologies plays key role in the practice of medicine such as old fashioned bone marrow transplants is replaced by Hematopoietic stem cell transplantation, capacity of cells in drug discovery. Cell therapy overlap with different therapies like, gene therapy, tissue engineering, cancer vaccines, regenerative medicine, and drug delivery. Establishment of cell banking facilities and production, storage, and characterization of cells are increasing volumetric capabilities of the cell therapy market globally. Initiation of constructive guidelines for cell therapy manufacturing and proven effectiveness of products, these are primary growth stimulants of the market.

Global Cell Therapy Technologies Market: Drivers and RestraintsThe growth of cell therapy technologies market is highly driven by, increasing demand for clinical trials on oncology-oriented cell-based therapy, demand for advanced cell therapy instruments is increasing, owing to its affordability and sustainability, government and private organization , investing more funds in cell-based research therapy for life-style diseases such as diabetes, decrease in prices of stem cell therapies are leading to increased tendency of buyers towards cell therapy, existing companies are collaborating with research institute in order to best fit into regulatory model for cell therapies.Moreover, Healthcare practitioners uses stem cells obtained from bone marrow or blood for treatment of patients with cancer, blood disorders, and immune-related disorders and Development in cell banking facilities and resultant expansion of production, storage, and characterization of cells, these factors will drive the market of cell therapy technologies during forecast period.

Do Inquiry Before Purchasing Report Here: https://www.maximizemarketresearch.com/market-report/global-cell-therapy-technologies-market/31531/#inquiry

On the other hand, the high cost of cell-based research and some ethical issue & legally controversial, are expected to hamper market growth of Cell Therapy Technologies during the forecast period

AJune 2016, there were around 351 companies across the U.S. that were engaged in advertising unauthorized stem cell treatments at their clinics. Such clinics boosted the revenue in this market.in August 2017, the U.S. FDA announced increased enforcement of regulations and oversight of clinics involved in practicing unapproved stem cell therapies. This might hamper the revenue generation during the forecast period; nevertheless, it will allow safe and effective use of stem cell therapies.

Global Cell Therapy Technologies Market: Segmentation AnalysisOn the basis of product, the consumables segment had largest market share in 2018 and is expected to drive the cell therapy instruments market during forecast period at XX % CAGR owing to the huge demand for consumables in cell-based experiments and cancer research and increasing number of new product launches and consumables are essential for every step of cell processing. This is further expected to drive their adoption in the market. These factors will boost the market of Cell Therapy Technologies Market in upcoming years.

On the basis of process, the cell processing had largest market share in 2018 and is expected to grow at the highest CAGR during the forecast period owing to in cell processing stage,a use of cell therapy instruments and media at highest rate, mainly in culture media processing. This is a major factor will drive the market share during forecast period.

Global Cell Therapy Technologies Market: Regional AnalysisNorth America to held largest market share of the cell therapy technologies in 2018 and expected to grow at highest CAGR during forecast period owing to increasing R&D programs in the pharmaceutical and biotechnology industries. North America followed by Europe, Asia Pacific and Rest of the world (Row).

Browse Full Report with Facts and Figures of Cell Therapy Technologies Market Report at: https://www.maximizemarketresearch.com/market-report/global-cell-therapy-technologies-market/31531/

Scope of Global Cell Therapy Technologies Market

Global Cell Therapy Technologies Market, by Product

Consumables Equipment Systems & SoftwareGlobal Cell Therapy Technologies Market, by Cell Type

Human Cells Animal CellsGlobal Cell Therapy Technologies Market, by Process Stages

Cell Processing Cell Preservation, Distribution, and Handling Process Monitoring and Quality ControlGlobal Cell Therapy Technologies Market, by End Users

Life Science Research Companies Research InstitutesGlobal Cell Therapy Technologies Market, by Region

North America Europe Asia Pacific Middle East & Africa South AmericaKey players operating in the Global Cell Therapy Technologies Market

Beckman Coulter, Inc. Becton Dickinson and Company GE Healthcare Lonza Merck KGaA MiltenyiBiotec STEMCELL Technologies, Inc. Terumo BCT, Inc. Thermo Fisher Scientific, Inc. Sartorius AG

MAJOR TOC OF THE REPORT

Chapter One: Cell Therapy Technologies Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Cell Therapy Technologies Market Competition, by Players

Chapter Four: Global Cell Therapy Technologies Market Size by Regions

Chapter Five: North America Cell Therapy Technologies Revenue by Countries

Chapter Six: Europe Cell Therapy Technologies Revenue by Countries

Chapter Seven: Asia-Pacific Cell Therapy Technologies Revenue by Countries

Chapter Eight: South America Cell Therapy Technologies Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Cell Therapy Technologies by Countries

Chapter Ten: Global Cell Therapy Technologies Market Segment by Type

Chapter Eleven: Global Cell Therapy Technologies Market Segment by Application

Chapter Twelve: Global Cell Therapy Technologies Market Size Forecast (2019-2026)

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Lumawant Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: sales@maximizemarketresearch.com

Contact:+ 919607065656/ +919607195908

Website: http://www.maximizemarketresearch.com

Here is the original post:
Global Cell Therapy Technologies Market Industry Analysis and Forecast (2018-2026) - Markets Gazette

Cancer cells to be tested in zero gravity on Chinese Space Station – E&T Magazine

Cancer cells are to be transported into space to see if weightlessness can stop their growth, in one of nine research projects destined for the new China Space Station (CSS) in 2022.

Upon completion, the CSS will include a cancer research project called Tumours in Space, headed by a Canadian researcher based in Norway. The project will examine the roles of both microgravity and cosmic radiation in tumour growth and development. The project is one of just nine selected by the UN Office for Outer Space Affairs (UNOOSA) and the China Manned Space Agency (CMSA) under their programme to provide scientists from all over the world with the opportunity to fly experiments on the CSS.

The plan is to send three-dimensional stem cell organoids from both healthy and cancer tissue from the same person into space. Here we will study mutations and look at how the cells DNA is affected by weightlessness and cosmic radiation, said the projects principal investigator Tricia L. Larose.

The experiment will rely on three-dimensional cancerous tumours, called organoids. These organoids are grown from adult human stem cells, which are a kind of cell that can divide indefinitely and create different types of cells in doing so. Researchers have perfected their ability to grow organoids so they actually form tiny structures that mimic different organs. Larose theorises that the cancer organoid growth will slow or stop when they are not affected by Earths gravity. Previous research on two-dimensional cells has shown that weightlessness has an influence on gene expression linked to tumour development.

When we look at mutational signatures in cancer cells, there is a lot of noise. The noise is something we simply do not know a lot about, she said. Part of my experimental process is identifying new causes of that noise, and some of that might be gravity

Her theory is that some of the unknown noise in the cancer cells is there as a result of gravity. Since both healthy cells and cells with cancer are affected by gravity, the researchers should be able to detect this in the fingerprints in all our cells.

Im looking for the molecular fingerprint for the gravitational force, she said; this could help explain the meaning of some of the noise in the cancer cells.

She added that the mutational signature of gravity has never been studied or even proposed as a concept. The experiment will also test how cosmic radiation affects the DNA of the healthy organoids and whether this leads to mutations and cancer. The various causes of cancer, such as smoking, UV radiation and ionizing radiation, also leave mutational signatures. Identifying mutational signatures from cancer-causing exposures can be used for risk prediction, eventually leading to better diagnostics and therapeutics.

My ground-based research with ionising radiation will also help us understand the side effects of radiation therapy for cancer patients on Earth, she said.

The studies of cosmic radiation will also help with understanding the cancer risk for astronauts on long-duration missions in the space station, or longer journeys, such as to Mars.

The biggest challenge with human spaceflight and exploration for long-duration missions to Mars and beyond, is the cancer risk for crew due to exposure of cosmic radiation. By identifying the mutational signature of cosmic radiation and comparing that to the known signature of ionising radiation, we may be better able to predict risk and protect crew on a long-duration space mission Larose said.

It is thought that astronauts on a mission to Mars would be exposed to at least 60 per cent of the total radiation dose limit recommended for their career during the journey alone to and from the Red Planet.

Sign up to the E&T News e-mail to get great stories like this delivered to your inbox every day.

Link:
Cancer cells to be tested in zero gravity on Chinese Space Station - E&T Magazine

Bone Therapeutics to present preclinical data on the osteogenic properties of ALLOB in bone repair at 27th Annual Meeting of the European Orthopaedic…

Press release

Gosselies, Belgium, 2 October 2019, 7am CEST BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the leading biotech company focused on the development of innovative cell and biological therapies to address high unmet medical needs in orthopaedics and bone diseases, announces that the Company will today present at the 27th Annual Meeting of the European Orthopaedic Research Society (EORS), in Maastricht, The Netherlands.

The Annual EORS Meeting is Europe's Summit for orthopaedic research and is attended by scientists, clinicians and entrepreneurs in the field. In the oral presentation, Bone Therapeutics will highlight additional preclinical in vitro and in vivo results demonstrating the potent osteogenic properties of its allogeneic bone-forming cell therapy platform, ALLOB, to promote bone-formation and improve fracture healing in relevant models.

ALLOB is the Companys allogeneic product that consists of human bone-forming cells derived from cultured bone marrow mesenchymal stem cells of healthy adult donors, and is manufactured through a proprietary, scalable production process. ALLOB successfully completed two Phase II studies in two indications and the Company is on track to submit a Clinical Trial Application with the regulatory authorities before the end of the year to allow the start of the next clinical development phase in patients with delayed-union fractures.

Presentation Details:

Title: Injectable cryopreserved allogenic bone-forming cells derived from bone marrow MSC (ALLOB) display potent osteogenic and bone repair propertiesAuthors: Sylvain Normand, Delphine De Troy, Coline Muller, Pierre-Yves Laruelle, Anna Tury, Sandra PietriSession: Cellular Regenerative Medicine (FP16)Date: Wednesday, 2 October 2019Time: 5:30pm CESTLocation: Room 08, Maastricht Exhibition & Congress Centre (MECC), Maastricht, The Netherlands

About Bone Therapeutics

Bone Therapeutics is a leading biotech company focused on the development of innovative products to address high unmet needs in orthopaedics and bone diseases. Based in Gosselies, Belgium, the Company has a broad, diversified portfolio of bone cell therapy and an innovative biological product in later-stage clinical development across a number of disease areas, which target markets with large unmet medical needs and limited innovation.

Bone Therapeutics core technology is based on its allogeneic cell therapy platform (ALLOB) which uses a unique, proprietary approach to bone regeneration, which turns undifferentiated stem cells from healthy donors into bone-forming cells. These cells can be administered via a minimally invasive procedure, avoiding the need for invasive surgery, and are produced via a proprietary, cutting-edge manufacturing process.

The Companys ALLOB product pipeline includes a cell therapy product candidate that is expected to enter PhaseII/III clinical development for the treatment of delayed-union fractures and a PhaseII asset in patients undergoing a spinal fusion procedure. In addition, the Company is also developing an off-the-shelf protein solution, JTA-004, which is expected to enter PhaseIII development for the treatment of pain in knee osteoarthritis.

Bone Therapeutics cell therapy products are manufactured to the highest GMP (Good Manufacturing Practices) standards and are protected by a broad IP (Intellectual Property) portfolio covering ten patent families as well as knowhow. Further information is available at http://www.bonetherapeutics.com.

Contacts

Bone Therapeutics SAThomas Lienard, Chief Executive OfficerJean-Luc Vandebroek, Chief Financial OfficerTel: +32 (0) 71 12 10 00investorrelations@bonetherapeutics.com

International Media Enquiries:Consilium Strategic CommunicationsMarieke VermeerschTel: +44 (0) 20 3709 5701bonetherapeutics@consilium-comms.com

For French Media and Investor Enquiries:NewCap Investor Relations & Financial CommunicationsPierre Laurent, Louis-Victor Delouvrier and Arthur RouillTel: + 33 (0)1 44 71 94 94bone@newcap.eu

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors` current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person`s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Read more:
Bone Therapeutics to present preclinical data on the osteogenic properties of ALLOB in bone repair at 27th Annual Meeting of the European Orthopaedic...

Global Stem Cell Therapy Market Report, 2019-2030 : Focus on Treatment Type, Cell Source, Indication and Competitive Landscape – Space Market Research

The global stem cell therapy market growth has been primarily attributed to the major drivers in this market such as the increasing prevalence of chronic diseases, rising number of clinical trials for cell-based therapy, steady investment, and consolidation in the regenerative medicine market, and favorable regulatory environment.

Get free pdf sample : https://www.marketindustryreports.com/pdf/32

Key Players in the Stem Cell Therapy Market are:

Market Definition: Stem Cell Therapy Market

Stem cells are human cells that have the ability to develop into various cell types such as muscle cells, brain cells they also have the unique ability to repair damaged tissue. Stem cells are divided into two major categories namely: embryonic stem cells and adult stem cells. The embryonic stem cell that is being used to conduct research today came from unused embryos resulting from an in vitro fertilization process which were later donated to science. These embryonic stem cells are pluripotent this basically means that they can turn into more than one type of cell. There are two types of adult stem cells- one of the type comes from fully developed tissues, such as the brain, the skin, and even bone marrow. The second type is induced pluripotent stem cells. These are adult stem cells that have been manipulated in a laboratory to take on characteristic of embryonic stem cells which enables them to turn into more than one type of cell.

The worldwide Stem Cell Therapy Market report give point by point data about the Stem Cell Therapy Market with a fitting examination of a few parameters and patterns impacting its advancement at a worldwide premise.

Scope of the Market :

The stem cell therapy market research provides a holistic view of the stem cell therapy market in terms of various factors influencing it, including regulatory reforms, and technological advancements.

The scope of this report is centered upon conducting a detailed study of the products allied with the therapeutic application of stem cells. In addition, the study also includes exhaustive information on the unmet needs, perception on the new products, competitive landscape, market share of leading manufacturers, the growth potential of each underlying sub-segment, and company, as well as other vital information with respect to global stem cell therapy market.

Market Segmentation

Market drivers: Stem Cell Therapy Market

Market Restraints: Stem Cell Therapy Market

Key Developments: CRISPR Technology Market

Stem cell therapy is accelerating at a huge growth circle that promises a potential for diversified career opportunities.

Get exclusive discount on report : https://www.marketindustryreports.com/discount/32

Table of Contents

INTRODUCTION

RESEARCH METHODOLOGY

In light of the examination of affecting development and constraining parameters, the exact information showing the future development pattern of the market can be gotten, which is altogether clarified in the Stem Cell Therapy Market research report. The data with respect to the moving toward circumstances that can help the market capitalization is additionally incorporated into the report. The report likewise involves fundamental data, for example, yearly income age, advertise esteem, use, yearly deals, and other significant measurable information, with respect to the key market contenders which incorporate a few associations, firms, item makers, sellers, and wholesalers.

Get exclusive discount on report : https://www.marketindustryreports.com/discount/32

Read More About Report Click Here:

About Us

Market Industry Reports is a global leader in market measurement and advisory services. It is 100% subsidiary of Maniks Systems Pvt Ltd. The firm has always been at the forefront of innovation to address the worldwide industry trends and opportunities.

Contact Us-

2nd Floor, Manikchand Ikon,

B-Wing, Dhole Patil Road,

Sangamwadi, Pune 411 001

Email: [emailprotected]Phone: +1 347 767 5477 ( US )+ 91 8956 767 535 ( IN )Website: https://www.marketindustryreports.com/Follow Us- LinkedIn | Twitter | Facebook

Visit link:
Global Stem Cell Therapy Market Report, 2019-2030 : Focus on Treatment Type, Cell Source, Indication and Competitive Landscape - Space Market Research

WWE Hall Of Famer Edge returning to the ring? – Wrestling News

Never say never when you talk about wrestling returns but it seemed like Edge would never step in the ring again due to his neck issues.

However, as reported in the Wrestling Observer Newsletter, Edge got a new deal from WWE by negotiating with both sides (assumed to be AEW) and he ended up with a significant offer to stay with WWE.

Edge did a spear during the SummerSlam Kickoff show, the first thing hes done in the ring in years since he couldnt be cleared to take bumps and he has been training hard and is in great shape. Dave Melzer noted that the idea of Edge wrestling again has been talked about privately but it is not known if he can get cleared by WWE doctors.

Meltzer also noted that people in creative are under the impression that he will never wrestle again. It should be noted that they would not know anything since it would be kept a secret from most people in the company if he were to wrestle again.

Edge recently left the Edge and Christian podcast and Christian hinted that you havent seen the last of Edge and you never know what he will do next.

On his last podcast, Edge said, To be perfectly honest, I think I could do a match tomorrow. I might be blown up but Id be OK. Its just from what I know with the WWE medical staff, they wont allow. It is what it is, right?

He also said that hes been considering getting stem cell therapy. Rey Mysterio credits stem cell therapy for healing his knee issues and Kevin Nash says he feels better than he has in years due to stem cell therapy. Edge also said that a doctor told him that his neck could be relatively healthy within five years.

Edge said the following about wrestling one more match: Just from the stuff Ive experienced in the last eight years and the things Ive done physically, its like I could pull off one. Im not saying I go back and do a years worth.

More here:
WWE Hall Of Famer Edge returning to the ring? - Wrestling News

Out of this world: Zionsville doctor sends osteoblast cells into space to study drug effects – Current in Carmel

Dr. Melissa Kacena and her team are continuing with the second phase of a two-part bone-healing study which involves mice and space.

Kacena and a team from the Indiana University School of Medicine planned two phases for a project. The first was to study femur fractures in 40 mice to learn the effects of bone-healing when introduced to weightlessness. The second examined results of two drugs when introduced to osteoblast cells in space.

Dr. Melissa Kacena is researching how osteoblast cells react to certain drugs while in space. (Photo illustration)

The first phase was completed in 2017. The second is ongoing.

Cells were launched on a SpaceX CRS-18 launch July 25 at Cape Canaveral, so that Kacena and other scientists could study the effects of a drug called bone morphogenetic protein-2, or BMP-2, which is commonly used to facilitate bone-healing in patients, and another called thrombopoietin, or TPO, most often used to increase platelets in blood that Kacena discovered can also be used to heal bone.

Dr. Tien-Min Gabriel Chu of the IU School of Dentistry co-invented the utility patent for the use of thrombopoietic agents for bone healing.

The osteoblast cells returned from space last month. An analysis should be complete by the end of the year.

Initially, the mice study was supposed to be conducted after the cell study, but because of problems with the cell spaceflight hardware that killed the cells, the order switched.We leap-frogged the order and did the bone-healing study first. We are still processing those tissues from the mice, and we are getting amazing data. Its very interesting, said Kacena, a Zionsville resident. Some data was recently published in scientific reports. We are finding some very interesting things that are not yet published. We are seeing what we hypothesized.

BMP-2, which orthopedic surgeons use for bone-healing, works through mechanical loading, so weight-bearing patients heal efficiently. The drug Kacena is proposing doesnt require loading for the bone to heal properly.

Ours has an advantage up in space flight, or if a patient is bedridden, she said.

The cells in space will be used to examine the effects of BMP-2 and TPO.

One of the reasons we are looking at this is BMP-2 has a risk of developing cancer, a small percentage, Kacena said.

Other side effects of BMP-2 include overgrowth of bone, which can cause spinal fusion.

If we can find something that doesnt have these side effects, this would be a better process, Kacena said.

Because bone cells grow differently in space, Kacena believes cell growth will improve if a patient takes TPO.

We think the cells with the TPO will grow better than the cells with BMP-2, she said

If research proves the hypothesis, TPO could be highly beneficial for astronauts who spend long periods of time in space.

If someone is bedridden or in space flight, they lose 1 to 3 percent of bone mass per month, Kacena said. Osteoporosis causes a loss of 1 percent per year. (Astronauts in space) are usually around 30 to 40 years old and theyre losing more (bone mass) in one month than somebody with osteoporosis loses in a year. Right now, we dont think bone mass stops or plateaus, so they may lose a third of their skeleton (mass), so we knew that testing these drugs on these cells is a good first indication whether it will be helpful in an unloaded environment in space.

The drug could also assist in healing fractures and benefit patients with osteoporosis or military veterans who have been injured while serving.

Thats our overall goal, to improve fracture healing for all patients the soldiers, people with osteoporosis or people in car accidents, Kacena said.

Kacena said the drug patent was approved and the team is moving forward with pre-clinical trials.

Melissa Kacena, center, observes as undergraduate Aamir Tucker, left, and post-doctoral fellow Paul Childress practice a surgical technique that will be used on 40 mice before they are launched into space for the first phase of a two-part project. (File photo by Ann Marie Shambaugh)

Although Dr. Melissa Kacena feels strongly about testing the effects of bone-healing drugs on mice and osteoblast cells in space, she also stresses the importance of STEM, or science, technology, engineering and mathematics, education for students. She invited eight Indiana University students to attend the space launch for the second phase of her project.I really care about STEM for kids in high school and kids in college. Thats why I really worked hard to give so many of my students the opportunity to come down there and see what was happening, Kacena said.

Most of the students were medical students.

Especially for me as Im getting older, theyre going to be my doctors eventually, and I want them to be really knowledgeable. What we learn in the clinic we can translate it to out of the clinic, and vice versa, she said.For more, visit medicine.iu.edu/blogs/bone-healing-in-space/.

More:
Out of this world: Zionsville doctor sends osteoblast cells into space to study drug effects - Current in Carmel

Digital health, Unicorns and what the smart money is chasing – BizNews

*This content is brought to you byOrbvest

ByHennie Bezuidenhoudt*

The revolutionary advances that technology continues to make in healthcare, have resulted in many medical breakthroughs and innovations. These have been driven by data collection, AI (Artificial Intelligence), machine learning, robotics, 3D printing, stem cell technologies and genome sequencing amongst others.

I would like to take a slightly different tack and pose the question. Amongst all these huge developments in healthcare, what medical innovations will (or already do) win the most investment?

To put it another way What disruptive medical innovations are the smart money chasing?

This article, the first of two around this subject, focuses on two key areas of the massive advancements taking place and the investment in the healthcare sector. So lets look at Digital health and Unicorns in 2019.

I would like to acknowledge and give credit to CB Insights, who devised a detailed report on this subject from which I have derived much of the information in this article. They are, in their own words, a tech market intelligence platform that analyses millions of data points on venture capital, start-ups, etc. most of the information derived from this report, is focussed around the USA, which is the global leader in many of the areas discussed.

Digital innovations have brought so many momentous changes to healthcare systems and these have just escalated through 2019. A good example is the use of software for the easier retrieving, tracking and saving of information regarding various illnesses and their treatment.

A few significant examples of Digital health innovations are:

This is one of the areas where the smart money is seen to be going. Even though in 2019 Digital health at 32% is taking a slightly smaller share of the global overall healthcare pie the funding is still escalating.

CB Insights summed up the phenomenal on-going rise in Digital health funding, as being on the rise for the second straight quarter. Total Digital health funding was $3.5B, up 23% from the first quarter of 2019.

Further to this, there are more deals being done in this sector with 371 in the second quarter, as opposed to 354 in the first. North America still holds dominance for Digital health investments and New York is the hottest metro Digital health investment area.

The last few years, as a result of the need for research and development as well as the implementing of all the medical advancements, the USA in particular has been a good time to be a healthcare or biotech start up business.

In the first half of 2018, healthcare start-ups globally raised $15 billion in funding. According to Forbes, this is the most raised in the first half of the year in the last decade. By July of 2018, a new crop of unicorns (these are start-ups with valuations of over $1 billion) were created, while some existing ones increased their already multi-billion-dollar valuations.

According to the CB Insights report, there are 38 VC-backed Digital health unicorns worth a combined $90.7B! Twenty-one of these are in the USA! Their total valuation in 2019 also continues to grow as a result of continued mega-rounds to existing unicorns, such as Tempus and Doctolib etc.

The value of these companies is immeasurable, as they are the major contributors to research and development. Just one example is Tempus the start-up founded by Groupon founder Eric Lefkofsky whos aim is to use data to come up with better cancer treatments, using both clinical and genetic data from the tumours of cancer patients.

I have just touched the tip of the iceberg here and will continue to show that global disruptors in the world of healthcare are drawing massive funding and inviting solid investment in its future.

Watch this space for my next article, which will give some insights into the roles being played by AI, MIP, Mental health and global healthcare investment trends. Unequivocally, this is what the smart money is chasing.

Continue reading here:
Digital health, Unicorns and what the smart money is chasing - BizNews

DNA Nanomachines Are Opening Medicine to the World of Physics – Singularity Hub

When I imagine the inner workings of a robot, I think hard, cold mechanics running on physics: shafts, wheels, gears. Human bodies, in contrast, are more of a contained molecular soup operating on the principles of biochemistry.

Yet similar to robots, our cells are also attuned to mechanical forcesjust at a much smaller scale. Tiny pushes and pulls, for example, can urge stem cells to continue dividing, or nudge them into maturity to replace broken tissues. Chemistry isnt king when it comes to governing our bodies; physical forces are similarly powerful. The problem is how to tap into them.

In a new perspectives article in Science, Dr. Khalid Salaita and graduate student Aaron Blanchard from Emory University in Atlanta point to DNA as the solution. The team painted a futuristic picture of DNA mechanotechnology, in which we use DNA machines to control our biology. Rather than a toxic chemotherapy drip, for example, a cancer patient may one day be injected with DNA nanodevices that help their immune cells better grab ontoand snuff outcancerous ones.

For a long time, said Salaita, scientists have been good at making micro devices, hundreds of times smaller than the width of a human hair. Its been more challenging to make functional nano devices, thousands of times smaller than that. But using DNA as the component parts is making it possible to build extremely elaborate nano devices because the DNA parts self-assemble.

Just as the steam engine propelled civilization through the first industrial revolution, DNA devices may fundamentally change medicine, biological research, and the development of biomaterials, further merging man and machine.

When picturing a tiny, whirling machine surveying the body, DNA probably isnt the first candidate that comes to mind. Made up of long chains of four lettersA, T, C, and GDNA is normally secluded inside a tiny porous cage in every cell, in the shape of long chains wrapped around a protein core.

Yet several properties make DNA a fascinating substrate for making mechano-machines, the authors said. One is its predictability: like soulmates, A always binds to T, and C with G. This chemical linking in turn forms the famous double helix structure. By giving the letters little chemical additions, or swapping them out altogether with unnatural synthetic letters, scientists have been able to form entirely new DNA assemblies, folded into various 3D structures.

Rather than an unbreakable, immutable chain, DNA components are more like Japanese origami paper, or Lego blocks. While they cant make every single shapetry building a completely spherical Death Star out of Legothe chemistry is flexible enough that scientists can tweak its structure, stiffness, and coiling by shifting around the letters or replacing them with entirely new ones.

In the late fall of 1980, Dr. Nadrian Seeman was relaxing at the campus pub at New York University when he noticed a mind-bending woodcut, Depth, by MC Escher. With a spark of insight, he realized that he could form similar lattice shapes using DNA, which would make it a lot easier for him to study the molecules shape. More than a decade later, his lab engineered the first artificial 3D nanostructurea cube made out of DNA molecules. The field of DNA nanotechnology was born.

Originally considered a novelty, technologists rushed to make increasingly complex shapes, such as smiley faces, snowflakes, a tiny world map, and more recently, the worlds smallest playable tic-tac-toe set. It wasnt just fun. Along the way, scientists uncovered sophisticated principles and engineering techniques to shape DNA strands into their desired structures, forming a blueprint of DNA engineering.

Then came the DNA revolution. Reading and writing the molecule from scratch became increasingly cheaper, making it easier to experiment with brand-new designs. Additional chemical or fluorescent tags or other modifications gave scientists a direct view of their creations. Rather than a fringe academic pursuit, DNA origami became accessible to most labs, and the number of devices rapidly explodeddevices that can sense, transmit, and generate mechanical forces inside cells.

If you put together these three main components of mechanical devices, you begin to get hammers and cogs and wheels and you can start building nano machines, said Salaita.

Salaita is among several dozen labs demoing the practical uses of DNA devices.

For example, our cells are full of long-haul driver proteins that carry nutrients and other cargo throughout their interior by following specific highways (it eerily looks like a person walking down a tightrope). Just as too much traffic damages our roadways, changes in our cells logistical players can also harm the cells skeleton. Here, scientists have used DNA handles to measure force-induced changes like stretching, unfolding, and rupture of molecules involved in our cells distribution system to look for signs of trouble.

Then there are DNA tension sensors, which act like scales and other force gauges in our macroscopic world. Made up of a stretchable DNA spring to extend with force, and a fluorescent ruler that measures the extension, each sensor is anchored at one end (generally, the glass bottom of a Petri dish) and binds to a cell at the other. If the pulling force exceeds a certain threshold, the spring unfolds and quenches the fluorescent light in the ruler, giving scientists a warning that the cellular tugging is too strong.

The work may sound abstruse, but its implications are plenty. One is for CAR-T, the revolutionary cancer treatment that uses gene therapy to amp up immune cells with better graspers to target tumor cells. The kiss of death between graspers and tumors are extremely difficult to measure because its light and fleeting. Using a DNA tension sensor, the team was able to track the force during the interaction, which could help scientists engineer better CAR-T therapies. A similar construct, the DNA tension gauge tether, irreversibly ruptures under too much force. The gauge is used to track how stem cells develop into brain cells under mechanical forces, and how immune cells track down and recognize foreign invasion.

[Immune] T cells are constantly sampling cells throughout your body using these mechanical tugs. They bind and pull on proteins on a cells surface and, if the bond is strong, thats a signal that the T cell has found a foreign agent, explained Salaita. DNA devices provide an unprecedented look at these forces in the immune system, which in turn could predict how strongly the body will mount an immune response.

To the authors, however, the most promising emerging DNA devices dont just observethey can also generate forces. DNA walkers, for example, uses DNA feet to transport (and sort) molecular cargo while walking down a track also made of DNA strands. When the feet bind to the track (A to T, C to G), it releases energy that propel the walker forward.

Even more exciting are self-assembling DNA machines. The field has DNA-based devices that transmit, sense and generate mechanical forces, the authors said. But eventually, their integration will produce nanomachines that exert mechanical control over living systems.

As costs keep dropping, the authors believe well witness even more creative and sophisticated DNA nanomachines.

Several hiccups do stand in the way. Like other biomolecules, foreign DNA can be chopped up by the bodys immune system as an invader. However, the team believes that the limitation wont be a problem in the next few years as biochemistry develops chemically-modified artificial DNA letters that resist the bodys scissors.

Another problem is that the DNA devices can generate very little forceless than a billionth the weight of a paperclip, which is a little too low to efficiently control forces in our cells. The authors have a solution here too: coupling many force-generating DNA units together, or engineer translators that can turn electrical energy into mechanical forcesimilar to the way our muscles work.

Fundamentally, any advancements in DNA mechanotechnology wont just benefit medicine; they will also feed back into the design of nanomaterials. The techniques, tools and design principlesare not specific to DNA, the authors said. Add in computer-aided design templates, similar to those used in 3D printing, and potentially anyone can dream up a nano-machine design and make it a reality, said Salaita.

Image Credit: Emory University. DNA mechanotechnology expands the opportunities for research involving biomedicine and materials sciences, says Khalid Salaita, right, professor of chemistry at Emory University and co-author of the article, along with Aaron Blanchard, left, a graduate student in the Salaita Lab.

View original post here:
DNA Nanomachines Are Opening Medicine to the World of Physics - Singularity Hub

PTPRU, As A Tumor Suppressor, Inhibits Cancer Stemness By Attenuating | OTT – Dove Medical Press

Jiayi Gu,1,* Zhiqi Zhang,2,* Tingyuan Lang,3,* Xinlin Ma,1 Linxi Yang,1 Jia Xu,1 Cong Tian,4 Kun Han,4 Jiangfeng Qiu1

1Department of Gastrointestinal Surgery, Renji Hospital Shanghai Jiao Tong University School of Medicine, Shanghai 200127, Peoples Republic of China; 2Department of General Surgery, Shanghai Jiao Tong University Affiliated Sixth Peoples Hospital, Shanghai 200233, Peoples Republic of China; 3Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital and Chongqing Cancer Institute and Chongqing Cancer Hospital, Chongqing 400030, Peoples Republic of China; 4Department of Medical Oncology, Shanghai Jiao Tong University Affiliated Sixth Peoples Hospital, Shanghai 200233, Peoples Republic of China

*These authors contributed equally to this work

Correspondence: Jiangfeng QiuDepartment of Gastrointestinal Surgery, Renji Hospital Shanghai Jiao Tong University School of Medicine, No.160 Pujian Road, Pudong New Area, Shanghai 200127, Peoples Republic of ChinaTel +86 138 1687 3899Fax +86 21 6373 0455Email qif0228@126.com

Background: PTPRU is an important signaling molecule that regulates a variety of cellular processes; however, the role of PTPRU in cancer development has remained elusive. Here, we report that PTPRU serves as a tumor suppressor that inhibits cancer stemness by attenuating Hippo/YAP signaling pathway.Methods: Primary cancer cells and cell line cells were used in the study. The gene expression data were downloaded from R2 analysis and visualization platform and KaplanMeier analysis was performed to study the relationship between survival and PTPRU expression. qRT-PCR and Western blot were employed to study the expression of target genes in tissues and cells. Sphere and colony formation, proliferation, migration activities and the expression of stem cell and EMT markers were employed for characterizing the stemness. Gene manipulation was achieved by lentivirus-mediated gene delivery system. Luciferase reporter gene assay was used to study the transcriptional activity of the promoter, and ChIP-qPCR was employed to study the target binding sequence of the protein. Spearman correlation analysis was performed to study the correlation between two genes. Students t-test was used for determination of the significance between two experimental groups.Results: PTPRU is downregulated in colorectal and gastric cancer tissues and cancer stem cells. High expression of PTPRU predicts poor prognosis. Overexpression of PTPRU attenuates the stemness of gastric cancer stem cells and knockdown of PTRPU improves the maintenance of the stemness of cancer stem cells. Mechanistic analysis showed that PTPRU inhibits Hippo/YAP signaling by suppressing the expression of YAP in a transcriptional level. Overexpression of YAP restored PTPRU-induced inhibited stemness of gastric cancer stem cells.Conclusion: PTPRU serves as a tumor suppressor that inhibits the stemness of cancer stem cell by inhibiting Hippo/YAP signaling pathway.

Keywords: PTPRU, cancer stem cells, Hippo/YAP signaling, gastric cancer, colorectal cancer

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Read the original here:
PTPRU, As A Tumor Suppressor, Inhibits Cancer Stemness By Attenuating | OTT - Dove Medical Press

Keeping the Gene Expression of Sex Chromosomes in Balance – Technology Networks

Researchers at Karolinska Institutet in Sweden have uncovered a chromosome-wide mechanism that keeps the gene expression of sex chromosomes in balance in our cells. The findings shed light on molecular reasons for early miscarriage and could be important for the emerging field of regenerative medicine. The study is published in Nature Structural and Molecular Biology.

The genes in our cells are packaged into 23 large units of DNA called chromosomes. The sex chromosomes, X and Y, differ from all other chromosomes in that they are only present as one active copy per cell instead of two. This renders a copy-number imbalance between genes located on sex chromosomes and the rest of our genome. Now researchers at Karolinska Institutet have figured out how our cells manage to double the expression of X-chromosome genes to achieve balance.

By examining gene expression dynamics in fine detail in female and male embryonic and somatic cells, the researchers found that genes on the X chromosome produced waves of gene products at a faster tempo than other chromosomes.

"The X chromosome generates 'bursts' of gene expression at higher rate that other chromosomes, pointing to the involvement of special DNA elements called enhancers in maintaining an elevated X-chromosome expression" says Bjrn Reinius, the principal investigator at the Department of Medical Biochemistry and Biophysics, who directed the study.

In female cells, carrying two X chromosomes, the increased tempo established on one X-chromosome copy during the same developmental window in which the second X-copy became inactivated. 'X inactivation' is a previously characterized mechanism that keeps one X chromosome silent in women, resulting in patches of cells expressing either the maternal or paternal copy. Male cells, carrying only one X chromosome, instead maintained a constantly fast rhythm of expression throughout developmental phases and cell types.

"Failure to establish X-chromosome dosage compensation during the early female embryogenesis is lethal and leads to early spontaneous abortion" Reinius says. "With the new knowledge, we better understand how the cells' gene expression network becomes destabilised."

According to the researchers, the findings represent a breakthrough in understanding sex-chromosome gene regulation. Understanding these chromosome-wide mechanisms could also be important in the field of regenerative medicine, since the reprogramming of cells may disturb the X-chromosome dosage balance in a gender-specific manner.

Reference: Larsson, Coucoravas, Sandberg and Reinius. 2019.X-chromosome upregulation is driven by increased burst frequency. Nature Structural and Molecular Biology. DOI: https://doi.org/10.1038/s41594-019-0306-y.

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

See original here:
Keeping the Gene Expression of Sex Chromosomes in Balance - Technology Networks